Citius Pharmaceuticals Inc
$ 0.87
1.85%
20 Apr - close price
- Market Cap 19,205,700 USD
- Current Price $ 0.87
- High / Low $ 0.90 / 0.83
- Stock P/E N/A
- Book Value 3.57
- EPS -2.46
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.48 %
- 52 Week High 2.48
- 52 Week Low 0.63
About
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. The company is headquartered in Cranford, New Jersey.
Analyst Target Price
$6.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-13 | 2025-12-23 | 2025-08-12 | 2025-05-12 | 2025-02-12 | 2024-12-27 | 2024-08-12 | 2024-05-14 | 2024-02-14 | 2023-12-29 | 2023-08-14 | 2023-05-12 |
| Reported EPS | -0.38 | -0.46 | -0.8 | -1.27 | -1.3 | -1.589 | -0.06 | -0.05 | -0.06 | -0.08 | -0.06 | -0.07 |
| Estimated EPS | -0.3 | 0.05 | 0.05 | 0.11 | -1.25 | -0.04 | -0.05 | -0.06 | 0.13 | -0.02 | -0.05 | -0.04 |
| Surprise | -0.08 | -0.51 | -0.85 | -1.38 | -0.05 | -1.549 | -0.01 | 0.01 | -0.19 | -0.06 | -0.01 | -0.03 |
| Surprise Percentage | -26.6667% | -1020% | -1700% | -1254.5455% | -4% | -3872.5% | -20% | 16.6667% | -146.1538% | -300% | -20% | -75% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CTXR
2026-04-08 19:39:05
Citius Pharmaceuticals is gaining significant clinical and commercial traction for its LYMPHIR therapy, developed by its oncology subsidiary, Citius Oncology. The therapy is attracting attention for its potential use before CAR-T therapy in patients with diffuse large B-cell lymphoma (DLBCL), and the company is preparing to attend the USCLC Workshop 2026 to discuss clinical experiences with cutaneous T-cell lymphoma (CTCL). This increased recognition validates Citius's focus on innovative oncology solutions.
2026-04-06 22:32:49
Citius Pharmaceuticals (NASDAQ:CTXR) held its 2026 annual meeting where shareholders elected seven members to its board of directors for a one-year term. The company's shareholders also ratified Wolf & Company, P.C. as their independent registered public accounting firm for the fiscal year ending September 30, 2026. The information was based on an SEC filing.
2026-04-06 21:39:49
Citius Pharmaceuticals (CTXR) held its 2026 annual meeting where shareholders elected seven directors for one-year terms and ratified Wolf & Company, P.C. as the independent registered public accounting firm for fiscal year 2026. Spark, TipRanks’ AI Analyst, rates CTXR as Neutral due to ongoing losses and cash burn, despite a low-debt balance sheet and positive developments for LYMPHIR. The stock currently holds a Hold rating from analysts with a $0.67 price target.
2026-04-06 20:39:49
Citius Pharmaceuticals, Inc. shareholders have re-elected their board of directors and approved Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2026. The key figures from the vote, including shares for and withheld for individual directors as well as the auditor ratification, were disclosed following the 2026 Annual Meeting. All seven directors, including Leonard Mazur and Myron Holubiak, were elected for a one-year term.
2026-04-01 09:09:24
This page provides a comprehensive overview of Citius Pharmaceuticals (CTXR) SEC filings, including 10-K, 10-Q, 8-K reports, and insider trading forms. It features AI-powered summaries of recent filings, such as a $6.0M direct offering to fund LYMPHIR's launch and insider stock disposals. The company is preparing for the commercial launch of its FDA-approved immunotherapy, LYMPHIR, but faces liquidity issues with negative working capital and cash expected to fund operations only through September 2025.
2026-04-01 08:40:38
Citius Pharmaceuticals reported strong early commercial momentum for LYMPHIR, demonstrating rapid institutional adoption with 83% of target accounts reviewing the product and broad payer coverage secured for approximately 80% of lives. The company is seeing sequential growth in orders and no reported reimbursement denials, while continuing its commercial buildout efforts.
